SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

Haduvio

TRVI·Trevi Therapeutics, Inc.
BULLISH
Drug Impact Rating7/10
Trial phase
Phase 3
Time to market
If Phase 3 trials succeed, a New Drug Application submission could occur in 2028-2029, with potential FDA approval and launch in 2029-2030 for the IPF chronic cough indication, assuming standard review timelines.
Why 7/10
The next hard catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027 (within ~6-12 months). Haduvio is Trevi's sole pipeline asset, making this a make-or-break binary for the company, but the exact timing within 2027 is not precisely dated, capping the score at 7.
Actionable Insight BULLISH

The next major catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027. Positive data would validate the Phase 2b signal and likely drive the stock toward the $28 mean analyst target; negative data would be a severe blow given Haduvio is Trevi's only pipeline asset. A Phase 2 start in non-IPF ILD chronic cough is planned for Q1 2027, and the cash runway into 2030 eliminates near-term financing risk.

Price Chart

Loading chart...

Executive Summary

Haduvio (oral nalbuphine ER) is Trevi Therapeutics' sole pipeline asset, an investigational dual-mechanism opioid receptor modulator in Phase 3 development for chronic cough. The drug met its primary endpoint in the Phase 2b CORAL trial (N=165) for IPF-related chronic cough, with results published in JAMA. Two pivotal Phase 3 trials (OCEAN-1 and OCEAN-2) are actively recruiting, with topline data expected in 2027 and 2028. GSK's exit from the chronic cough space after a Phase 3 failure in July 2026 leaves Trevi as the only active developer in its three target indications. The company has a cash runway into 2030, strong institutional backing, and a unanimous analyst Buy consensus with a mean price target implying roughly 90% upside.

How It Works

Haduvio is an extended-release formulation of nalbuphine, a drug that works on opioid receptors in the brain and nervous system to suppress the cough reflex. It acts as a kappa opioid receptor agonist (turns on one type of receptor) and a mu opioid receptor antagonist/partial agonist (blocks or partially activates another type). This dual mechanism is designed to reduce chronic coughing without the full addictive potential of classic opioids like morphine.

Trial Status

Two pivotal Phase 3 trials (OCEAN-1 and OCEAN-2) for IPF-related chronic cough are actively recruiting. OCEAN-1 was initiated in Q2 2026 and OCEAN-2 in Q3 2026. A Phase 2 trial in non-IPF ILD chronic cough is planned to start in Q1 2027. Phase 2b CORAL (IPF cough, N=165) and Phase 2a RIVER (refractory chronic cough, N=66) are both completed with positive results.

The Two-Sided Case

▲ Bull Case5
Haduvio met its primary endpoint in the Phase 2b CORAL trial (N=165) for IPF-related chronic cough, with results published in JAMA in January 2026, providing strong peer-reviewed validation of the mechanism.
GSK discontinued its rival chronic cough drug camlipixant in July 2026 after a Phase 3 failure, leaving Trevi as the only active developer in its three targeted chronic cough indications and removing a major competitive threat.
Analyst consensus is Strong Buy (17 Buy/Strong Buy, 1 Hold, 0 Sell) with a mean price target of $28.18, implying roughly 90% upside from the current $14.81 price; BMO Capital has a $36 target.
Institutional accumulation has been heavy: FMR LLC added 56% to its position in Q2 2026 (now $234M), Woodline Partners more than doubled its stake, and multiple new buyers emerged in Q2 and Q3 2026.
Cash runway extends into 2030 per the Q3 2026 earnings call, eliminating near-term dilution risk while the Phase 3 program completes.
▼ Bear Case4
Haduvio is an opioid-based therapy (kappa agonist / mu antagonist), which carries regulatory, abuse-liability and safety-perception risks that could limit commercial adoption or draw FDA scrutiny.
Phase 3 trials are inherently binary; positive Phase 2 data does not guarantee Phase 3 success, and the OCEAN-1/OCEAN-2 readouts in 2027-2028 are the only value-defining catalysts for this single-asset company.
Insider sales by director Michael Heffernan in September 2026 (about $594K total at ~$15/share, via a 10b5-1 plan) and institutional trims by Viking Global (-52% of position) and Citadel (full exit) in Q2 2026 signal some profit-taking near the stock's 52-week high.
Nausea, vomiting, dizziness and constipation were noted as potentially mu-mediated adverse effects in the CORAL trial, which could affect tolerability and compliance in a chronic-use population.

Upcoming Catalysts

  • Phase 3 OCEAN-1 topline data expected in 2027
  • Phase 3 OCEAN-2 topline data expected in 2028
  • Phase 2 start in non-IPF ILD chronic cough planned for Q1 2027
  • Potential additional data presentations at medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Trevi Therapeutics, Inc. 8-K TRVI ·Originating report

Sources · 10

Hover a chip for the title
1 rttnews.com2 markets.businessinsider.com3 seekingalpha.com4 markets.businessinsider.com5 streetinsider.com6 healio.com7 bioworld.com8 insidermonkey.com9 seekingalpha.com10 ajmc.com